Jones Financial Companies
RVNC

Jones Financial Companies’s Revance Therapeutics, Inc. RVNC Stock Holding History

Jones Financial Companies’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,034
Closed -$9.22K – 3897
2024
Q4 		$9.22K Sell
3,034
-2,201
-42% -$9.59K ﹤0.01% 2554
2024
Q3 		$28.1K Sell
5,235
-518
-9% -$2.57K ﹤0.01% 1839
2024
Q2 		$14.8K Buy
+5,753
New +$19.6K ﹤0.01% 1632

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jones Financial Companies's RVNC Position: Q1 2025 in Review

Jones Financial Companies sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 3,034 shares — an estimated $9.22K sold.

Jones Financial Companies first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $28.1K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Jones Financial Companies reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Jones Financial Companies sold 3,034 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $9.22K.
  • Jones Financial Companies first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
  • Jones Financial Companies's Revance Therapeutics, Inc. position peaked at $28.1K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Jones Financial Companies's 13F filing for Q1 2025, filed 16 May 2025.